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Genome-Wide Association Studies (GWAS) have identified several loci contributing to lung 
cancer and COPD risk independently; however, inflammation-related pathways likely harbor 
additional lung cancer risk-associated variants in biologically relevant immune genes that differ 
dependent on COPD. We selected single nucleotide polymorphisms (SNPs) proximal to 2069 
genes within 48 immune pathways. We modeled the contribution of these variants to lung 
cancer risk in a discovery sample of 1932 lung cancer cases and controls stratified by COPD 
status and validation sample of 953 cases and controls also stratified by COPD. There were 43 
validated SNPs in those with COPD and 60 SNPs in those without COPD associated with lung 
cancer risk. Further, 29 of 43 and 28 of 60 SNPs demonstrated a statistically significant 
interaction with COPD in the pooled sample. These variants demonstrated tissue-dependent 
effects on proximal gene expression, enhanced network connectivity, and resided together in 
specific immune pathways. These results reveal that key inflammatory related genes and 
pathways, not found in prior GWAS, impact lung cancer risk in a COPD-dependent manner. 
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Genetic variation identified in this study supplement prior lung cancer GWAS and serve as a 
foundation to further interrogate risk relationships in smoking and COPD populations. 






 We evaluated the impact of genetic variation in immune and inflammatory genes and 
pathways on lung cancer in metropolitan Detroit lung cancer cases and controls with or without 
COPD. We demonstrate that variation in these genes and pathways impact lung cancer risk in a 
COPD dependent manner.  
 
Introduction 
 Lung cancer is the leading cause of cancer death in the United States and the second 
most frequently occurring cancer type 1. Approximately 80-90% of lung cancer is attributable to 
smoking 2. Rates of current smoking have declined by  8% from 1990-2014; however, lung 
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cancer incidence during this period decreased by only 2.3% 3, and the large population of at-risk 
former smokers in the US remains a public health concern.   
 Tobacco smoke exposure is closely associated with the development of a spectrum of 
lung diseases including emphysema, chronic bronchitis, chronic obstructive pulmonary disease 
(COPD) and lung cancer. Accumulating evidence suggests that prolonged exposure to cigarette 
smoke initiates lung and airway irritation giving rise to chronic inflammatory infiltration, closely 
linked to the remodeling of airway mucosa seen in airway obstruction as well as in the 
degradation of alveolar interstitium described in emphysema 4-6. This chronic inflammatory 
state is believed to underlie the 2-3 fold increase of lung cancer risk in individuals with COPD 7, 
8.  
 Although smoking accounts for a majority of lung cancers, aggregation among families, 
occurrence in never smokers, and variability in risk among ever smokers suggests the existence 
of contributing genetic factors 9. Lung cancer GWAS have identified several genotype-
phenotype associations in regions such as 15q25.1 (CHRNA5, CHRNA3), 5p15.33 (CLPTM1L, 
TERT) and 6p21.33 (BAG6/BAT3/MSH5) that are consistent and reproducible across multiple 
populations 10-16. This agnostic approach is useful for identifying novel genes and generating 
hypotheses about biological mechanisms previously unknown to be involved in lung cancer 
etiology. However, with genome-wide corrections for multiple testing, these studies restrict 
their reporting to the few top SNPs that pass stringent statistical thresholds, potentially 
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excluding other significant SNPs with strong biological evidence supporting a role in lung cancer 
susceptibility. Therefore, the incorporation of knowledge on genes and pathways relevant to 
lung inflammation and tumorigenesis represents a complementary approach to generate novel 
hypotheses regarding the genetic contributors to risk and mechanistic differences in lung 
carcinogenesis.  
 We explored the contribution of genetic variation in immune pathways to lung cancer 
risk, separately by COPD status, in a discovery sample of 1008 cases and 924 controls and 
validated findings in an independent sample of 498 cases and 455 controls from the same 
population of inference.  This was followed by evaluating whether the impact of each validated 
SNP was significantly heterogeneous among those with and without COPD as well as evaluating 




 The Wayne State University (WSU), McLaren Health Care (MHC) and Henry Ford Health 
System (HFHS) Institutional Review Boards approved the procedures used in collecting and 
processing participant information, and written informed consent was obtained from all 
subjects prior to participation.  The INHALE study was initiated in 2012 and has been previously 
described 17. Briefly, lung cancer cases were enrolled at the Karmanos Cancer Center in Detroit 
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or its network sites, or at HFHS in Detroit or its network sites, and volunteer controls were 
enrolled from the same geographic areas from which cases were drawn, preferentially matched 
to cases on smoking status (91.7% ever-smoking cases vs. 91.1% ever-smoking controls). 
Participants were 21-89 years of age, and were asked to complete an interview, low-dose chest 
CT scan and spirometry, and provide saliva, blood and tumor tissue samples. Further eligibility 
was restricted to those who carried health insurance (in the event medical follow-up was 
required based on a clinical finding on the CT or spirometry), and never had taken Amiodarone 
or been diagnosed with bronchiectasis or cystic fibrosis. Additionally, controls had never been 
diagnosed with lung cancer nor had surgical removal of any portion of either lung.  
  
Data collection 
 Age, race, gender, history of COPD, family history of lung cancer and smoking history 
were collected in interviews. Pack years were calculated by multiplying the number of years 
smoked by the average number of cigarettes smoked per day divided by 20. Pulmonary 
function tests with spirometry were either performed by trained technicians in accordance with 
ATS guidelines 18 at the time of enrollment or spirometry results from pulmonary function tests 
(PFTs) were abstracted from medical records if completed within 6 months of the INHALE 
interview date. For analysis purposes, COPD was defined based on spirometry (FEV1/FVC < 
0.70); where FEV1/FVC was missing (14%), self-reported history of COPD was used.  




Genotyping and selection of immune system pathways 
 Genotyping was performed using the Illumina Multi-Ethnic GWAS/Exome Array (MEGA), 
which covers 1.7 million SNPs across the genome. The chip was designed to capture variation in 
ethnically diverse populations including Europeans, Asians, African Americans and Hispanics. 
The variants originate from sequencing discoveries, other GWAS panels, and published disease 
association studies. Immune system related genes and pathways were obtained from either the 
Reactome database or a published study of inflammation pathway genes and lung cancer risk 19, 
20. The assembled immune system gene and pathway list contains manually curated, peer-
reviewed pathway annotations cross-referenced with multiple databases including KEGG, 
Ensembl, and Uniprot by Reactome staff (Supplemental Table 1). Pathway annotations were 
included during the overrepresentation pathway analysis. MEGA SNP hg19 build 37 coordinates 
were cross-referenced with immune pathway gene locations according to the UCSC genome 
browser 21. In addition to intragenic SNPs, SNPs within flanking, proximal regulatory regions 
were included if contained within +/- 2kB of the gene region based upon ENCODE proximal 
regulatory data 22, 23.  After removing invariant sites, there were 77,777 SNPs mapped to 2,015 
immune pathway genes. SNPs were then filtered based on GenTrain score (<0.7), call rate <0.95 
and inconsistent genotypes based on 19 CEPH sample replicates (99.88% concordance overall); 
71,737 SNPs passed these quality control criteria.  We required at least 15 minor allele carrier 
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cases for each SNP evaluated (across discovery and validation samples) to avoid unstable effect 
estimates due to very rare SNPs. Thus, our analysis set consisted of 43,953 SNPs.   
 
Statistical Analysis 
 The total number of INHALE participants with genotype data available was divided into a 
‘discovery’ and ‘validation’ sample as follows: subjects were stratified by case-control status and 
randomly assigned to either the discovery or validation set by a ratio of 2:1. In this way the 
discovery set represented 2/3 of the total INHALE sample and the validation set represented the 
remaining 1/3 of the sample.  There were no significant differences between the discovery and 
validation samples for any of the covariates used in this analysis (Supplemental Tables 2 and 3). 
Discovery and validation samples were further stratified by COPD status and analyzed separately. 
We estimated African ancestry based on a panel of 128 ancestry informative markers 
(AIMs) described by Kosoy and colleagues 24; 122 AIMs were genotyped and passed QC standards 
in the MEGA panel. Assuming Hardy-Weinberg Equilibrium, expected genotype relative 
frequencies were calculated for both European (‘EUR’) and African (‘AFR’) populations based on 
1000 Genomes samples. For each of the three genotypes per AIM, the proportion of African 
ancestry was computed as f(AFRj)/(f(AFRj)+f(EURj)), where f(AFRj) is the expected frequency for 
genotype j in Africans and f(EURj) is the expected frequency for genotype j in Europeans. Samples 
were then assigned a probability of African ancestry for each SNP corresponding to their 
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observed genotype. These probabilities were summed and scaled for each individual to a 
standard uniform as  
∑ (𝑋𝑋𝑗𝑗−𝑎𝑎𝑗𝑗)𝑗𝑗
∑ (𝑏𝑏𝑗𝑗−𝑎𝑎𝑗𝑗)𝑗𝑗
, where Xj is the probability of African ancestry for the jth AIM, and 
aj and bj are the minimum and maximum possible probabilities for the jth AIM, respectively. This 
method of scoring ancestry was previously tested against principal component analysis (PCA) for 
correcting for population sub-structure and was found to perform similarly 24. We verified these 
findings by conducting a PCA-based ancestry estimate with EIGENSTRAT using all 43,953 immune 
pathway-based SNPs and then comparing this estimate with African ancestry score. The top 
eigenvector explained ~74% of all variance explained by significant eigenvectors (n=19). African 
ancestry score and this top eigenvector were highly correlated (Spearman correlation: 0.832, p = 
1×10-16)(Supplemental Figure S1). 
   In both the discovery and validation samples, logistic regression modeling was used to 
estimate individual SNP effects on lung cancer risk, separately among those with and without 
COPD, assuming an additive (per allele effect) genetic model. SNP effects were adjusted for age, 
gender, African ancestry score and pack years. Due to the exploratory nature of this study, we 
used a threshold of α=0.05 for carrying forward SNPs in either the COPD or no COPD discovery 
samples for testing in the respective validation sample. We assessed race-specific SNP effects 
by modeling each of the validated SNPs separately in whites and African Americans (also 
adjusting for ancestry score), combining the (COPD or no COPD) discovery and validation 
samples.  We also used logistic regression modeling to determine whether the effects of any of 
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the validated SNPs were statistically dependent on COPD in the pooled sample by incorporating 
an interaction term, the cross-product of SNP genotype (0, 1 or 2) and COPD status (0 or 1). For 
interaction modeling, we analyzed the combined sample of cases and controls with and without 
COPD. SNP effects on tissue-specific gene expression were modeled as cis expression 
quantitative trait loci (eQTL) as described previously by the Genotype-Tissue Expression (GTEx) 
project version 7 25. Select GTEx tissues were evaluated for eQTL effects, lung and blood, to 
narrow the eQTL search to tissues directly involved in tobacco mediated lung injury. Multiple 
test corrections were computed for eQTL effects separately in each tissue. Network 
connectivity of genes was assessed using STRING as described previously 26. Overrepresentation 
analysis was conducted using the hypergeometric distribution within the 48 immune pathways 
containing 2015 genes. 
 
Data Availability 
The data that support the findings of this study are available from the corresponding author 
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A description of the INHALE case-control sample stratified by COPD is presented in Table 1. 
Lung cancer cases with COPD were more often white, ever smokers, and more likely to have a 
family history of lung cancer relative to controls with COPD. Cases in both strata (COPD versus 
no COPD) were more likely to be older and heavier smokers relative to controls, in addition to 
being diagnosed most often with adenocarcinoma and at later stages (stage III/IV, 72%). The 
total INHALE sample (N=2885) was subsequently split into a discovery (66%, n=1932/2885) and 
a validation (33%, n=953/2885) sample using random sampling. There were no significant 
differences between either cases in the discovery and validation samples or controls in the 
discovery and validation samples (Supplemental Tables 2 and 3).  
 
Variant association testing 
There were 43,953 immune-centric SNP association tests performed separately in 
samples with and without COPD (Supplementary Figures S2 and S3). SNP genotypes were 
modeled additively and adjusted for age, African ancestry, gender and pack years of smoking 
exposure. We carried forward 1,837 SNPs among cases and controls with COPD and 2,130 SNPs 
among cases and controls without COPD with a nominal p-value < 0.05 for evaluation in the 
validation sample. Upon testing these SNPs in the validation sample, 43 of 1,837 also met the 
α=0.05 threshold and were concordant in their direction of effect in the COPD validation 
sample (Supplemental Table 4). For cases and controls without COPD, 60 of 2,130 SNPs met 
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these criteria in the validation sample (Supplemental Table 5). There were no validated SNPs in 
common to both strata. 
To formally evaluate the context-dependency of validated SNPs in both the COPD and 
no COPD strata, we modeled interactions between COPD and each SNP in the pooled sample 
(discovery and validation samples combined). Interaction test results are presented in Table 2 
for SNPs identified in individuals with COPD and Table 3 for SNPs identified in individuals 
without COPD. We considered an interaction test result of p<0.05 as sufficient evidence for 
context-dependency. We found significant COPD-dependent effects for 29 of 43 of the 
validated SNPs from the COPD stratum within 24 immune genes. Among the validated SNPs in 
samples without COPD, 28 of 60 SNPs had a significant interaction with COPD within 26 
immune pathway genes. Hence, out of 103 SNPs tested for context-dependency, 57 
demonstrated significant COPD-dependent effects. We observed consistent context-dependent 
associations among these 57 SNPs when lung cancer cases were stratified by histology 
(adenocarcinoma and squamous cell carcinoma, Supplemental Tables 6 and 7).   
 
Functional and biological significance 
Considering our variant selection strategy, SNPs were selected for their proximity (±2kB) 
to immune pathway genes and each SNP was assigned to a specific gene. Through this gene 
This article is protected by copyright. All rights reserved.
14 
 
assignment, we evaluated whether the genes represented by the 57 significant and context-
dependent risk loci demonstrated functional or biological importance.  
First, we interrogated the functional impact of risk notable SNPs on the expression of 
paired candidate genes using tissue-specific expression quantitative trait loci (eQTL) data from 
the GTEx consortium. We assessed eQTLs in two specimen types, lung tissue and whole blood 
leukocytes, to capture SNP functionality in the primary tissues relevant to lung inflammation 
(Table 4). Eleven risk significant and context-dependent SNP-gene pairs were significant eQTLs 
in lung, blood, or both tissues. Of variants notable for lung cancer risk with an interaction with 
COPD status (n=57), four SNPs demonstrated significant (p < 0.05) effects on paired candidate 
gene expression in lung tissue alone. Additionally, four SNPs demonstrated significant (p < 0.05) 
paired gene expression effects in whole blood leukocytes. Three SNP-gene pairs were 
significant in both tissues (CD96, NRG1 and UBE2O).  
As an alternative to functional characterization, we interrogated the biological 
significance of immunological genes implicated by context-dependent risk loci separately by 
COPD. First, we assessed the network connectivity of genes demonstrating context-dependent 
risk associations to determine whether these genes act in cohesive biological networks. 
Secondly, we assessed whether any of the immune pathways contained a greater number of 
loci-paired genes than we would expect by chance to identify the immunological pathways 
involved in lung cancer risk. To limit false positive results a significance threshold of α=0.01 was 
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used. In COPD cases and controls, eight functional protein-protein network interactions were 
identified among candidate genes with significant and context dependent lung cancer risk 
associations (n=24), which was not statistically significant (p = 0.238; Supplemental Figure 4A). 
The 24 gene candidates in the COPD strata were also not significantly overrepresented at 
α=0.01 within any of the 48 immune pathways evaluated (Figure 1A). In individuals without 
COPD, candidate genes (n=26) contained 20 functional protein-network associations 
(Supplemental Figure 4B), more than expected by chance (p = 0.0002). Two immune pathways, 
Fc-gamma receptor dependent phagocytosis (R-HSA-2029480) and DAP12 Interactions (R-HSA-
2172127), were significantly (p<0.01) overrepresented among these significant and context 
dependent lung cancer risk genes (Figure 1B).    
These data demonstrate that immune-centric risk loci whose effects differ by COPD 
collectively reside within specific immune networks, and several directly regulate the 
expression of these network genes in tissues relevant to lung cancer. 
 
Discussion 
In this study we investigated the role of inflammation in lung cancer susceptibility, localized 
to biologically relevant immune pathways, to identify immune and inflammatory variants linked 
to lung cancer risk in individuals with and without COPD. Previous studies have implicated 
inflammation in the development of lung cancer independent of tobacco smoke exposure, and 
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thus inflammation is thought to underlie the increased lung cancer susceptibility among those 
with COPD. However, prior scientific focus was limited to a narrower selection of inflammatory 
genes and processes 5, 27. Such studies implicated genetic variation near and within 
inflammatory genes in lung cancer susceptibility 28, 29, either within known candidate genes 
identified a posteriori utilizing gene ontology searches and customized genotyping 
methodology 20, 30, or by extracting inflammatory relevant variants from GWAS 31. We have 
complemented the efforts of previous studies, using an expanded inflammatory gene and 
pathway set paired with a high-density, multi-ethnic SNP array to determine which immune 
gene and pathway based loci confer lung cancer susceptibility in the presence and absence of 
COPD.  
Few studies to-date assessed the role of genetic loci in lung cancer risk in individuals dual 
phenotyped for COPD. A study performed by Young and colleagues investigated the link 
between known lung cancer risk loci (n=11) and COPD in a smoking population of Caucasian 
New Zealanders 32. They identified differential lung cancer risk effects in two variants that 
differed by COPD state and reported several other loci that may act as dual risk modifiers for 
lung cancer and COPD. Unfortunately, only a single inflammatory locus (rs2808630, CRP) was 
included in the study due to the limited scope of genotyping, and we were unable to validate 
any COPD dependent lung cancer risk associations within the CRP gene locus, which included 
rs2808630. Another such study conducted by Yang et al. investigated whether known CHRNA3 
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lung cancer risk variants were also associated with COPD susceptibility and severity in a Chinese 
population of smokers, identifying a single significant association with potential mechanistic 
underpinnings 33. They, however, did not investigate associations between inflammatory 
processes, COPD, and lung cancer susceptibility.  
To expand upon these efforts, as well as to determine the COPD dependency of 
inflammatory gene and pathway variants in lung cancer risk, we conducted lung cancer 
association testing on 43,953 loci proximal (±2kB) to 2069 immune-centric genes in individuals 
separately by COPD status. We observed significant context-independent associations in the 
pooled discovery/validation samples for several genes (APOB, PARK2, and PRKG1). While SNPs 
in PRKG1 were also validated in the context-dependent analyses, none of the 57 SNPs were in 
common to both strata (nor were they in LD with each other). However, we did find several 
correlations (D’>0.9) between SNPs that were identified in samples with COPD and those 
without COPD.  LD was estimated using both D’ and r2 separately for white and African 
American samples; D’ values were used to determine strong associations due to the presence 
of lower frequency SNPs in the MEGA panel and the sensitivity of r2 to relative allele frequency 
differences between pairs of SNPs. Among white samples, three SNP pairs were in strong LD: 
rs2901600 in DNM3 (COPD) and exm113346 in SPTA1 (No COPD), rs10932427 in ERBB4 (COPD) 
and rs3749096 in EDAR (No COPD) and JHU_8.71282810 in NCOA2 (COPD) and rs73241640 in 
NRG1 (No COPD). No SNP pairs were in strong LD among African Americans. A lack of 
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substantial overlapping loci/gene associations between the COPD stratums provides evidence 
that the genetic risk profiles for lung cancer greatly differ in individuals susceptible to COPD as 
opposed to individuals without COPD. As such, these findings align with prior work highlighting 
divergent inflammatory processes in smokers who are susceptible to COPD as opposed to 
smokers who are not 34; and further, the divergent inflammatory processes likely contribute to 
the increased risk of lung carcinogenesis in individuals with COPD 35, 36.  
Next, we interrogated the functional and biological significance of the immune-centric risk 
candidates, separately by COPD state. Functional analyses identified 19% (11/57) of the risk 
significant variants as significant cis-eQTLs in tissues of primary interest: lung and whole blood 
leukocyte tissues. This suggests that these variants may impart risk through modulating the 
expression patterns of lung and immunological tissues. Risk variants with no detectable eQTL 
signals may still play a role in regulating immunological gene expression in cases where lung 
inflammation is present; GTEx style studies in populations with active lung disease will be 
necessary to elucidate these effects.  
Immune-centric gene candidates associated with lung cancer risk also demonstrated 
substantially more network connectivity in individuals without COPD (20 functional 
interactions) as opposed to individuals with COPD (8 functional interactions), despite the fact 
that approximately the same number of genes were represented in each stratum (24 in COPD 
versus 26 in no COPD). Immune-related risk signatures in smokers without COPD may reside in 
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a narrow biological process whereas immune-related risk signatures in smokers with COPD 
reside across a more broad biological process. Moreover, pathway analysis revealed several 
pathways with an overrepresentation of risk candidates. Two classical innate immune activation 
schemes were represented; DAP12 Interactions (R-HSA-2172127) and Fc-gamma receptor 
dependent phagocytosis (R-HSA-2029480). Pathway involvement of the candidates was distinct 
between individuals with and without COPD, as no pathway was enriched in both stratums. 
These findings provide a biological context by which these variants may be contributing to 
differential lung cancer risk in individuals with and without COPD. 
Due to known heterogeneity of minor allele relative frequencies between whites and 
African Americans, it is possible that race-specific effects exist among the 57 validated COPD-
dependent SNPs. Indeed, six of 29 SNPs with risk effects in COPD (rs868936562, rs61505577, 
rs72969686, rs73783372, rs1074822 and rs61731180) and 4 of 28 SNPs in the no COPD stratum 
(rs867806199, rs114240594, rs4149646 and rs78466637) were restricted to either whites or 
African Americans, due to very low relative allele frequencies in the other race (i.e., no valid 
test). These variants could prove useful in understanding race related lung cancer susceptibility 
patterns. Conversely, the remaining variants represent a race-independent inflammatory 
relationship in lung cancer susceptibility in individuals with or without COPD. This set of 
variants could serve as useful risk stratification loci in admixed smoking populations. 
Furthermore, neither the race dependent or independent variants were shared between 
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individuals with nor without COPD suggesting that the genetic risk profiles in lung cancer differ 
greatly in individuals susceptible to COPD as opposed to individuals without COPD regardless of 
an individual’s race.  
The strengths of this study lie in the recruitment of a large set of racially diverse cases and 
controls with a well-defined COPD phenotype as well as the targeting of variation within genes 
directly involved in immune functions. This has allowed us to stratify the study population by 
COPD status to interrogate the contribution of immune-related variation to lung cancer 
susceptibility. There are, however, limitations to the approach we have taken. The requirement 
that participants carry a valid health insurance policy may limit generalizability to those who 
either can afford private insurance, have employer-provided benefits or qualify for Medicaid. In 
the state of Michigan, uninsured cancer patients can apply for Medicaid and therefore the most 
appropriate control group is one that is also insured. In addition, clinically actionable findings 
on CT could not be ignored based on ethical grounds; thus, insured participants had a 
mechanism through which findings could be acted upon. Another potential weakness of this 
study was the choice of a relatively loose significance threshold of α=0.05 with no correction for 
multiple testing in the discovery phase of the analysis. Among the 43,953 SNPs, none were 
significant at a Bonferroni-corrected threshold (p≤1.1x10-6). However, we employed a stringent 
step-wise approach downstream to restrict our findings to the most consistent stratum-specific 
SNP effects. Likewise, the selection of the multi-ethnic genotyping array, while useful for a 
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population containing Caucasians and African Americans, limited our ability to externally 
validate variant findings in prior lung cancer risk datasets, ultimately leading us to use an 
internal validation set.  
Further research is necessary to determine the mechanistic link between risk-notable 
immune and inflammatory variants which differ by COPD states in at-risk populations. 
Moreover, the variants identified in this study will serve as a foundation to further interrogate 
the relationship of differential lung cancer risk profiling in individuals who have COPD as 
opposed to individuals who do not have COPD.  
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Figure 1. Pathway architecture of the significant risk candidates between COPD stratums. 
Legend: Pathway analysis plots of the significant lung cancer risk and COPD interaction 
candidates within the designated immune pathways chosen for this study. Overrepresentation 
significance values are plotted on the x-axis for each pathway with a line designating the 
significance threshold. (A) Pathway significance values for candidates identified in individuals 
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Former smokers may have lingering inflammation as a result of smoking, and this inflammation 
may be the reason that people with COPD have a 2- to 3-fold risk of lung cancer. Here the 
authors looked at a high-density, multiethnic SNP array to find variants linked to lung cancer risk 
which occur in genes involved in immune pathways. They found 43 SNPs associated with lung 
cancer in people with COPD, and 29 of the 43 showed significant biological interaction with 
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Tables and Figures 
 
Table 1. Description of INHALE lung cancer case-control sample (N=2885), stratified by COPD status. 













(n=933) p value 
Gender (n, %)       
    Male 291 (43.0) 208 (46.6) 0.228 387 (46.7) 421 (45.1) 0.512     Female 386 (57.0) 238 (53.4) 442 (53.3) 512 (54.9) 
Race (n, %)       
    White 435 (64.3) 240 (53.8) 0.001 545 (65.7) 573 (61.4) 0.060     African American 242 (35.7) 206 (46.2) 284 (34.3) 360 (38.6) 
Age (µ, SD) 64.6 (9.4) 62.5 (9.6) <0.001 62.3 (11.1) 59.4 (9.3) <0.001 
    <50 36 (5.3) 40 (9.0) 
0.027 
100 (12.1) 131 (14.0) 
<0.001     51-59 174 (25.7) 127 (28.5) 234 (28.2) 353 (37.8)     60-69 258 (38.1) 167 (37.4) 280 (33.8) 325 (34.8) 
    70+ 209 (30.9) 112 (25.1) 215 (25.9) 124 (13.3) 
Smoking status (n, %)       
    Never 19 (2.8) 30 (6.7) 0.002 119 (14.4) 106 (11.4) 0.060     Ever 658 (97.2) 416 (93.3) 710 (85.6) 827 (88.6) 
Pack years (µ, SD)* 50.5 (29.9) 36.9 (27.2) <0.001 41.2 (29.6) 30.4 (22.5) <0.001 
Family history of lung 
cancer 
      
    No 500 (73.9) 384 (86.3) <0.001 655 (79.1) 764 (81.9) 0.141     Yes 177 (26.1) 61 (13.7) 173 (20.9) 169 (18.1) 
    Missing 0 1  1 0  
Histology       
    Adenocarcinoma 330 (49.2)  
--- 
511 (61.6)   
    Squamous cell 173 (25.8)  139 (16.8)   
    Small cell 105 (15.7)  105 (12.7)  --- 
    other NSCLC 62 (9.3)  62 (7.5)   
    unknown/missing 7  12   
Stage       
    I 164 (24.6)  
--- 
116 (14.3)  
---     II 67 (10.0)  70 (8.6)      III 153 (22.9)  183 (22.5)  
    IV 283 (42.4)  443 (54.6)  
    Missing 10  17   
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Table 2. Tests of COPD x SNP interaction on lung cancer risk for the 43 validated SNPs in individuals 
with COPD 
SNP Gene CHR Position 
COPD x SNP 
interaction p 
value  
Pooled risk model results 
OR* 95% CI p value 
rs2932538 MOV10 1 113216543 0.055 0.73 (0.59,0.91) 0.004 
rs2901600 DNM3 1 171835654 <0.001 0.73 (0.61,0.87) 0.0005 
rs693 APOB 2 21232195 0.680 0.83 (0.69,0.99) 0.0437 
JHU_2.70774695 TGFA 2 70774696 0.025 4.34 (1.76,10.71) 0.0014 
rs10932427 ERBB4 2 213073615 0.012 0.6 (0.44,0.81) 0.001 
rs115435003 TRIP12 2 230629658 0.998 0.46 (0.23,0.94) 0.0325 
rs546530 TRIP12 2 230752964 0.077 1.3 (1.09,1.56) 0.004 
rs7570061 INPP5D 2 233977318 0.005 0.7 (0.57,0.86) 0.0006 
rs79048756 CD96 3 111323053 0.015 0.41 (0.24,0.68) 0.0007 
rs61505577 BMPR1B 4 95789665 0.015 2.48 (1.46,4.23) 0.0008 
rs73836068 BMPR1B 4 95891132 0.057 1.87 (1.29,2.72) 0.001 
JHU_6.117021274 KPNA5 6 117021275 0.010 0.4 (0.24,0.68) 0.0007 
6:125369362-CT RNF217 6 125369362 0.022 0.28 (0.11,0.7) 0.0062 
rs73783372 PARK2 6 162155477 0.015 2.54 (1.52,4.25) 0.0004 
JHU_7.54821275 SEC61G 7 54821276 0.070 4.37 (1.6,11.93) 0.004 
JHU_7.139540808 TBXAS1 7 139540809 0.052 0.65 (0.48,0.88) 0.0053 
JHU_8.71282810 NCOA2 8 71282811 0.030 0.24 (0.09,0.6) 0.0026 
rs4745646 TJP2 9 71769323 0.011 1.52 (1.18,1.95) 0.001 
rs688391 PRKCQ 10 6489652 0.312 1.34 (1.11,1.61) 0.0024 
rs3793727 PRKCQ 10 6508377 0.005 1.56 (1.26,1.93) <0.0001 
rs658230 PRKCQ 10 6508563 0.044 1.39 (1.16,1.67) 0.0005 
JHU_10.32320560 KIF5B 10 32320561 0.080 0.7 (0.55,0.88) 0.0021 
rs12252698 PRKG1 10 53608098 0.002 0.69 (0.54,0.89) 0.0037 
rs1937701 PRKG1 10 53608977 0.009 0.7 (0.57,0.86) 0.0007 
JHU_10.75843193 VCL 10 75843194 0.006 0.44 (0.26,0.75) 0.0025 
rs3127255 FBXW4 10 103370234 0.105 1.31 (1.07,1.6) 0.0086 
rs666432 TRIM29 11 120003533 0.003 1.48 (1.14,1.93) 0.0037 
rs4411364 TNFRSF19 13 24191374 0.029 1.43 (1.12,1.82) 0.0042 
rs9510787 TNFRSF19 13 24205195 0.034 1.43 (1.12,1.82) 0.0042 
rs1630 TNFRSF19 13 24249847 0.010 1.49 (1.22,1.82) 0.0001 
rs17446928 FOXO1 13 41212225 0.001 0.39 (0.25,0.6) <0.0001 
rs76294435 PPP2R5C 14 102274571 0.077 0.4 (0.25,0.65) 0.0002 
JHU_14.103934653 MARK3 14 103934654 0.099 0.73 (0.6,0.89) 0.0018 
rs55986634 DAPK2 15 64275645 0.180 0.71 (0.58,0.88) 0.0018 
rs75395345 PIAS1 15 68373718 0.993 1.26 (1,1.57) 0.0485 
rs2071501 CSK 15 75095157 0.033 0.54 (0.37,0.79) 0.0015 
JHU_16.4014963 ADCY9 16 4014964 0.049 1.46 (1.18,1.82) 0.0006 
rs933392 ADCY9 16 4032716 0.036 1.44 (1.16,1.79) 0.001 
exm1358199 UBE2O 17 74387284 0.023 1.39 (1.14,1.69) 0.0012 
JHU_18.49961949 DCC 18 49961950 0.020 0.68 (0.53,0.88) 0.0028 
rs10414006 SPTBN4 19 41001921 0.010 0.62 (0.49,0.79) 0.0001 
rs11879349 NLRP4 19 56364210 0.041 0.62 (0.47,0.82) 0.0008 
exm2262720 PAK3 23 110379807 0.034 0.68 (0.52,0.88) 0.0033 
*Logistic model adjusted for age, gender, African ancestry score and pack years 
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Table 3. Tests of COPD x SNP interaction on lung cancer risk for the 60 validated SNPs in individuals 
without COPD 
SNP Gene CHR Position 
COPD x SNP 
interaction 
 p value  
Pooled risk model results 
OR* 95% CI p value 
exm69478 ASB17 1 76397972 0.156 1.29 (1.1,1.5) 0.0014 
JHU_1.108497389 VAV3 1 108497390 0.029 0.72 (0.58,0.89) 0.0022 
rs3754293 LAMTOR2 1 156024373 0.219 0.8 (0.69,0.93) 0.0028 
exm113346 SPTA1 1 158645965 <0.001 6.46 (2.37,17.63) 0.0003 
rs2230779 TRAF5 1 211533352 0.534 1.59 (1.18,2.14) 0.0024 
rs10929693 ATP6V1C2 2 10863267 0.435 0.8 (0.69,0.93) 0.0032 
exm175467 APOB 2 21225281 0.187 1.2 (1.02,1.43) 0.0316 
newrs676210 APOB 2 21231524 0.183 1.21 (1.02,1.43) 0.0299 
rs3749096 EDAR 2 109512428 0.044 1.34 (1.1,1.63) 0.0033 
rs13418730 WIPF1 2 175540594 0.048 0.68 (0.52,0.89) 0.0046 
rs7583875 AP1S3 2 224665694 0.062 0.8 (0.7,0.92) 0.0016 
JHU_3.18396523 SATB1 3 18396524 0.127 0.35 (0.2,0.6) 0.0001 
rs80069959 KCNH8 3 19223049 0.069 0.58 (0.4,0.84) 0.0040 
JHU_3.119275362 CD80 3 119275363 0.019 0.53 (0.36,0.77) 0.0009 
rs953239 TRPC1 3 142446205 0.003 1.23 (1.07,1.41) 0.0036 
rs7623154 PIK3CA 3 178921158 0.020 1.25 (1.07,1.46) 0.0055 
JHU_5.16912953 MYO10 5 16912954 0.029 2.24 (1.27,3.94) 0.0051 
JHU_5.35873123 IL7R 5 35873124 0.187 0.6 (0.43,0.84) 0.0034 
rs7726469 CAMK4 5 110586438 0.020 0.76 (0.65,0.9) 0.0015 
rs12153148 KLHL3 5 136964764 0.066 0.74 (0.62,0.88) 0.0006 
rs3777376 KLHL3 5 136965249 0.042 0.73 (0.61,0.87) 0.0005 
rs7774142 LY86 6 6642058 0.027 1.3 (1.12,1.5) 0.0007 
exm-rs3827784 LY86 6 6642405 0.031 1.31 (1.12,1.52) 0.0005 
JHU_6.137043810 MAP3K5 6 137043811 0.016 2.19 (1.23,3.89) 0.0075 
rs56247201 PARK2 6 162702092 0.191 0.5 (0.33,0.74) 0.0006 
rs35537854 RPS6KA2 6 167072030 0.128 0.6 (0.42,0.85) 0.0041 
JHU_7.30352063 ZNRF2 7 30352064 0.001 0.15 (0.04,0.53) 0.0033 
JHU_7.30393775 ZNRF2 7 30393776 0.062 0.29 (0.14,0.62) 0.0014 
exm689348 TNFRSF10A 8 23049292 0.298 0.75 (0.62,0.92) 0.0047 
rs73241640 NRG1 8 31932616 0.031 0.39 (0.24,0.63) 0.0002 
rs11776203 NRG1 8 32419119 0.003 0.76 (0.63,0.92) 0.0039 
JHU_8.32431713 NRG1 8 32431714 0.446 0.42 (0.24,0.74) 0.0029 
rs1014306 DAPK1 9 90157451 0.317 1.33 (1.14,1.54) 0.0002 
rs12378686 DAPK1 9 90163570 0.547 1.3 (1.1,1.52) 0.0018 
JHU_9.90198587 DAPK1 9 90198588 0.152 0.58 (0.4,0.82) 0.0024 
rs10995319 PRKG1 10 52762887 0.125 1.32 (1.09,1.6) 0.0045 
rs7904024 PRKG1 10 52841790 0.022 1.28 (1.11,1.48) 0.0007 
JHU_10.83841723 NRG3 10 83841724 0.415 2.87 (1.4,5.86) 0.0038 
rs74153420 BMPR1A 10 88628433 0.287 2.4 (1.33,4.33) 0.0038 
JHU_10.93222022 HECTD2 10 93222023 0.486 1.46 (1,2.11) 0.0481 
JHU_10.123313013 FGFR2 10 123313014 0.020 1.49 (1.17,1.91) 0.0014 
rs548142 DYNC2H1 11 103315520 0.048 0.75 (0.65,0.86) 0.0001 
This article is protected by copyright. All rights reserved.
JHU_12.6438144 TNFRSF1A 12 6438145 0.016 1.83 (1.3,2.58) 0.0005 
JHU_12.26512936 ITPR2 12 26512937 0.011 3.4 (1.48,7.86) 0.0041 
rs61971164 STK24 13 99190397 0.072 0.73 (0.61,0.88) 0.0008 
rs17565502 TNFSF13B 13 108954304 0.061 1.26 (1.08,1.47) 0.0039 
JHU_14.23313974 MMP14 14 23313975 0.011 0.54 (0.35,0.82) 0.0038 
rs78656887 PSMC1 14 90734095 0.018 0.48 (0.31,0.76) 0.0016 
rs12441042 TLN2 15 62946064 0.085 0.79 (0.68,0.92) 0.0019 
rs74318887 MEF2A 15 100229061 0.027 0.46 (0.29,0.74) 0.0012 
rs76272325 PSMB6 17 4699845 0.172 0.5 (0.34,0.74) 0.0004 
JHU_17.5413392 NLRP1 17 5413393 0.055 0.79 (0.68,0.93) 0.0033 
JHU_17.40648111 ATP6V0A1 17 40648112 0.003 1.83 (1.33,2.51) 0.0002 
rs12949223 CD300LD 17 72589264 0.246 1.24 (1.07,1.44) 0.0050 
JHU_18.21773860 OSBPL1A 18 21773861 0.115 2.78 (1.49,5.17) 0.0012 
rs11082490 SIGLEC15 18 43412628 <0.001 1.53 (1.27,1.84) <0.0001 
rs58993112 MALT1 18 56412784 0.159 1.35 (1.11,1.64) 0.0023 
exm2253611 PDE4A 19 10546771 0.029 1.25 (1.08,1.45) 0.0027 
rs9676881 KEAP1 19 10596780 0.008 1.32 (1.14,1.53) 0.0002 
rs2898449 MX1 21 42814495 0.063 0.69 (0.54,0.87) 0.0020 
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Table 4. Significant eQTL and context-dependent lung cancer risk SNP-gene pairs in lung and whole blood leukocyte tissues 
SNP Gene CHR Position 














Significant eQTL SNP-gene pairs in individuals with COPD 
rs79048756 CD96 3 111323053 0.015 0.0007 3.7x10-4 0.016 1.8x10-5 6.6x10-4 
rs4745646 TJP2 9 71769323 0.011 0.0010 >0.05 - 7.2x10-4 0.008 
rs3793727 PRKCQ 10 6508377 0.005 0.0000 >0.05 - 0.007 0.049 
rs666432 TRIM29 11 120003533 0.003 0.0037 0.036 0.25 >0.05 - 
exm1358199 UBE2O 17 74387284 0.023 0.0012 4.6x10-6 4.0x10-4 <0.001 0.002 
Significant eQTL SNP-gene pairs in individuals without COPD 
rs7623154 PIK3CA 3 178921158 0.020 0.0055 0.002 0.042 >0.05 - 
rs953239 TRPC1 3 142446205 0.003 0.0036 0.002 0.042 >0.05 - 
rs3777376 KLHL3 5 136965249 0.042 0.0005 >0.05 - 0.006 0.045 
rs11776203 NRG1 8 32419119 0.003 0.0039 0.044 0.28 8.1x10-10 6.0x10-8 
rs11082490 SIGLEC15 18 43412628 0.001 0.0000 >0.05 - 2.8x10-4 0.003 
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